Physician profile
Mark Perez
NPI 1720152473
$5,887.43
in general payments reported to CMS, 2019-2025
36 companies · $1,003 in 2025
The $1,003 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $294 · 2020: $206 · 2021: $676 · 2022: $1,048 · 2023: $1,291 · 2024: $1,370 · 2025: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,664.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,663.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,854.38 | 2019-2025 | Farxiga, Airsupra, Brilinta |
| Bayer Healthcare Pharmaceuticals INC. | $582.73 | 2022-2025 | |
| Abbvie INC. | $442.75 | 2021-2024 | |
| Pfizer INC. | $344.25 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $335.07 | 2019-2024 | Jardiance |
| Glaxosmithkline, LLC. | $253.37 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $241.35 | 2021-2025 | Ozempic, Rybelsus |
| Lilly USA, LLC | $218.32 | 2021-2025 | Jardiance, Mounjaro, Kisunla |
| Abbott Laboratories | $174.80 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Redhill Biopharma INC. | $165.13 | 2022-2023 | Aemcolo, Movantik, Talicia |
| Amgen INC. | $128.79 | 2023-2025 | Repatha, Otezla, Repatha |
| Cumberland Pharmaceuticals, INC. | $113.54 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $107.90 | 2019-2025 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $103.09 | 2023-2025 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $83.13 | 2024-2025 | Zoryve |
Show all 36 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Perez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.